Compare Raytheon Technologies Corp (RTX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs TransMedics Group Inc — how do they compare? Raytheon Technologies Corp trades at $194.15 (market cap $261.85B), while TransMedics Group Inc trades at $73.5 (market cap $2.54B). The key difference: Raytheon Technologies Corp is far larger — about 103.1× TransMedics Group Inc's market cap, and Raytheon Technologies Corp pays a 1.5% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| RTX | TMDX | |
|---|---|---|
Market Cap | $261.85B | $2.54B |
Sector | Industrials | Technology |
52-Week High | $212.16 | $150.42 |
52-Week Low | $149.17 | $61.99 |
Enterprise Value | $293.97B | $2.94B |
Dividend Yield | 1.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $193.51, down 0.44% today, with a bullish technical signal and strong analyst support. Recent contract wins, including a $515 million Navy radar deal (PRNewsWire, June 3, 2026), and earnings beats in Q4 2025 and Q1 2026 highlight operational momentum. Revenue growth accelerated to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock faces resistance near $196-$199, with support at $192.
The outlook remains positive given defense spending tailwinds and production expansions, but elevated P/E of 36.48 poses valuation risk. Analysts project 10% upside to a $213 consensus target, with no sell ratings. Key risks include debt levels and geopolitical volatility affecting contracts.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
